Introduction
============

Antimicrobial resistance (AMR), especially the appearance and dissemination of multiresistant bacteria, as well as the lack of alternative treatments, are a major threat to both clinical medicine and public health in Greece, elsewhere in Europe and globally. As stated in the recent World Health Organization (WHO) AMR action plans, an important cornerstone to control AMR is its surveillance \[[@r1]\].

Indeed, continuous monitoring of the emergence and evolution of resistance to key antimicrobials over time constitutes a crucial first step to estimate the burden of the problem, uncover trends, detect new resistance phenotypes, guide empirical antimicrobial treatment and measure the effect of interventions \[[@r2]\].

The routine results of the antimicrobial susceptibility tests performed daily in each hospital clinical laboratory are considered as a major resource for continuous, passive AMR surveillance since they are reliable and informative and can be collected on a daily basis without imposing any additional effort to the clinical microbiology laboratory.

Greece has been among the first countries with an electronic network based on routine susceptibility results since 1995. The Greek AMR surveillance system (WHONET-Greece) allows continuous monitoring at national level of bacterial antibiotic resistance in Greek hospitals based on the collection and processing of routine susceptibility data from the Laboratory Information System (LIS) of hospital laboratories using the WHONET software \[[@r3]\]. The data are publicly available ([www.mednet.gr/whonet](http://www.mednet.gr/whonet)) and have been continuously submitted to the European Antimicrobial Resistance Surveillance System (EARSS) and subsequently to the European Antimicrobial Resistance Surveillance Network (EARS-net) (<https://ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-andlaboratory-networks/ears-net>) as the annual Greek AMR data.

In the present collaboration, we sought to describe the trends of the relative isolation frequency (RIF) and the AMR rates among key bloodstream pathogens and their evolution over time for the period 2010--2017 as captured by the national continuous monitoring system of routine laboratory data in order to provide information for action to both clinicians and public health authorities in Greece.

Methods
=======

Study period and setting
------------------------

The study covered the 8-year period from January 2010 to December 2017. Twenty-five tertiary Greek hospitals, participating in the WHONET-Greece network and consistently reporting data for the entire period (a maximum of two non-consecutive semesters of non-reporting were missing in three hospitals), contributed to the study. The participating hospitals were distributed across the country and represented all four first-level nomenclature of territorial units for statistics (NUTS-1) regions of Greece. Moreover, the participating hospitals' bed capacity ranged from 178 to 908 beds and thus small (\< 200 beds), medium (200--500 beds) and large (\> 500 beds) public hospitals were represented ([Figure 1](#f1){ref-type="fig"}).

![Number of hospitals participating in the study and total bed capacity per first-level nomenclature of territorial units for statistics regions of Greece, WHONET-Greece AMR network, January 2010--December 2017 (n = 25 hospitals)](1900516-f1){#f1}

The antimicrobial susceptibility testing (AST) was performed in the hospitals' clinical laboratories by automated systems. All participating hospital laboratories performed internal quality controls, and they took part in the annual external quality assessment provided by the United Kingdom National External Quality Assessment Service (UK-NEQAS), offered by the European Centre for Disease Prevention and Control (ECDC).

Isolate collection and relative isolation frequency
---------------------------------------------------

During the 8-year period, routine susceptibility data of 50,488 key Gram-negative and Gram-positive bacterial isolates from blood cultures of hospitalised patients in the participating tertiary hospitals, representing the nine most clinically important species, were gathered and studied ([Table 1](#t1){ref-type="table"}). From each patient, only the first isolate per species was included. The RIF of each one of the studied bacterial species was defined as its proportion among the nine bacterial species included in the study, calculated per year and ward type.

###### Number of bloodstream bacterial isolates per year and species, from patients hospitalised in wards and ICUs of the 25 hospitals participating in the WHONET-Greece AMR network, 2010--2017 (n = 50,488 isolates)

  Microorganism                              Year of isolation   Total   \%                                                       
  ------------------------------------------ ------------------- ------- ------- ------- ------- ------- ------- ------- -------- -------
  **Number of bacteria isolated in wards**                                                                                        
  *Escherichia coli*                         1,048               1,044   1,074   1,121   1,124   1,157   1,337   1,213   9,118    26.2
  *Klebsiella pneumoniae*                    774                 708     672     728     713     756     754     772     5,877    16.9
  *Staphylococcus aureus*                    583                 598     631     621     533     590     659     633     4,848    13.9
  *Pseudomonas aeruginosa*                   417                 431     429     483     390     424     459     454     3,487    10.0
  *Acinetobacter baumannii*                  317                 346     390     348     384     456     416     471     3,128    9.0
  *Enterococcus faecalis*                    368                 365     414     379     363     377     414     430     3,110    8.9
  *Enterococcus faecium*                     248                 229     236     245     222     233     275     288     1,976    5.7
  *Proteus mirabilis*                        157                 181     201     188     203     237     249     206     1,622    4.7
  *Enterobacter* spp.                        224                 206     202     206     184     198     190     194     1,604    4.6
  Total in wards                             4,136               4,108   4,249   4,319   4,116   4,428   4,753   4,661   34,770   100.0
  **Number of bacteria isolated in ICUs**                                                                                         
  *Acinetobacter baumannii*                  652                 685     600     499     516     509     503     440     4,404    28.0
  *Klebsiella pneumoniae*                    625                 686     574     500     461     417     466     424     4,153    26.4
  *Pseudomonas aeruginosa*                   457                 361     353     415     329     246     278     239     2,678    17.0
  *Enterococcus faecalis*                    188                 217     196     158     142     148     197     149     1,395    8.9
  *Enterococcus faecium*                     130                 114     111     99      88      95      110     96      843      5.4
  *Staphylococcus aureus*                    101                 106     100     78      81      60      65      75      666      4.2
  *Proteus mirabilis*                        107                 115     103     54      60      75      69      72      655      4.2
  *Enterobacter* spp.                        78                  110     71      50      45      57      46      44      501      3.2
  *Escherichia coli*                         54                  57      43      60      50      42      60      57      423      2.7
  Total in ICUs                              2,392               2,451   2,151   1,913   1,772   1,649   1,794   1,596   15,718   100.0

AMR: antimicrobial resistance; ICUs: intensive care units; WHONET-Greece: Greek electronic surveillance system for monitoring AMR in hospitals based on routine data.

Classification of isolates in terms of antimicrobial susceptibility
-------------------------------------------------------------------

The classification of isolates as susceptible, intermediate or resistant (including, for enterococci with acquired aminoglycoside resistance, high-level resistance (HLR) to aminoglycosides) was based on the Clinical and Laboratory Standards Institute (CLSI) (<https://clsi.org>) clinical breakpoints, a system which was used in Greece for routine AST interpretation during the study period. The version of WHONET software we used for the analysis was equipped with CLSI 2017--2018 breakpoints. The isolates with intermediate susceptibility were grouped with the resistant ones, forming the non-susceptible group.

Data analysis
-------------

We focused on annual trends of both RIF for the bacteria included in the study and antimicrobial non-susceptibility rates for the key antimicrobial classes traditionally used for the treatment of Gram-negative and Gram-positive bacteraemia, as well as for the presence of multidrug resistance according to the interim standard definitions for acquired resistance \[[@r4]\]. The data from intensive care units (ICUs) were analysed separately from medical and surgical wards. To assess trends in proportions of non-susceptible isolates over time, we used the Cochran--Armitage χ^2^ test for trend. A p value of ≤ 0.05 was considered significant. Statistical analysis was performed using R version 3.4.3 for Windows.

Ethical statement
-----------------

For this observational study, since the confidentiality of the data was ensured by pseudo-anonymisation with unique codes for each included bacterial isolate, and data will not be identifiable back to the patient from whom they originated, an ethical approval was not needed.

Results
=======

Relative isolation frequency and trend analysis over time
---------------------------------------------------------

Concerning the RIF of the nine main pathogens among the bloodstream isolates from patients hospitalised in the wards ([Figure 2a](#f2){ref-type="fig"}), *Escherichia coli*was the most prevalent in each year of the study period with an annual RIF ranging from 25.3% to 28.1% (median: 26.0%). This was followed by *Klebsiella pneumoniae* (range: 15.8--18.7%; median: 17.0%), *Staphylococcus aureus* (range: 12.9--14.9%; median: 14.0%), *Pseudomonas aeruginosa* (range: 9.5--11.2%; median: 9.9%), *Enterococcus faecalis* (range: 8.5--9.7%; median: 8.9%), *Acinetobacter baumannii* (range: 7.7--10.3%; median: 9.0%), *Enterococcus faecium* (range: 5.3--6.2%; median: 5.6%), *Enterobacter* spp. (range: 4.0--5.4%; median: 4.6%) and *Proteus mirabilis* (range: 3.8--5.4%; median: 4.6%).

![Relative isolation frequency trend analysis of nine key bloodstream pathogens from patients hospitalised in (a) the wards (n = 34,770) and (b) the ICUs (n = 15,718) of the 25 hospitals participating in the WHONET-Greece AMR network, 2010--2017](1900516-f2){#f2}

Among the studied isolates from patients hospitalised in ICUs ([Figure 2b](#f2){ref-type="fig"}), *A. baumannii* was the most prevalent bloodstream isolate in each year of the study period with an annual RIF ranging from 26.1% to 30.9% (median: 27.9%) followed by *K. pneumoniae* (range: 25.3--28.0%; median: 26.1%), *P. aeruginosa* (range: 14.7--21.7%; median: 16.0%), *E. faecalis* (range: 7.9--11.0%; median: 8.9%), *E. faecium* (range: 4.7--6.1%; median: 5.3%), *S. aureus* (range: 3.6--4.7%; median: 4.3%), *P. mirabilis* (range: 2.8--4.8%; median: 4.5%), *Enterobacter* spp. (range: 2.5--4.5%; median: 3.0%) and *E. coli* (range: 2.0--3.6%; median: 2.7%).

Overall ([Figure 2](#f2){ref-type="fig"}, [2a,b](#f2){ref-type="fig"}), we observed a significant increasing trend in the RIF of *E. coli* (p ≤ 0.001), *P. mirabilis* (p = 0.004) and *A. baumannii* (p ≤ 0.001) from patients hospitalised in the wards while their RIF remained stable over the years in ICUs. In contrast, a significant decreasing trend was observed in the RIF of *K. pneumoniae* from ICUs (p = 0.028) and *Enterobacter* spp. (p = 0.002) from patients hospitalised in both wards and ICUs. As for *P. aeruginosa*, no trend was observed in its RIF irrespective of the hospitalisation unit. Concerning Gram-positive bloodstream pathogens, the RIFs of *S. aureus*, *E. faecalis* and *E. faecium* were stable without any trend over time in both the wards and ICUs.

Trends in antimicrobial resistance rates over time
--------------------------------------------------

All significant trends in AMR rates over time per microorganism and hospitalisation unit are shown in [Table 2](#t2){ref-type="table"} and more specifically described below.

###### Significant trends in antimicrobial resistance rates over time per microorganism and hospitalisation unit (wards or ICU), WHONET-Greece AMR network, 2010--2017 (n = 48,211)

  Antibiotic                                      Year of isolation   p value   Trend                                                                                                                                           
  ----------------------------------------------- ------------------- --------- ----------- ------ ----------- ------ ----------- ------ ----------- ------ ----------- ------ ----------- ------ ----------- ------ ---------- ------
  *Escherichia coli*                                                                                                                                                                                                            
  Ceftazidime non-susceptible                                                                                                                                                                                                   
  Wards                                           117/1,032           11.3      126/1,034   12.2   136/1,047   13.0   152/1,097   13.9   166/1,092   15.2   156/1,119   13.9   179/1,318   13.6   176/1,198   14.7   0.012      ↑
  Meropenem non-susceptible                                                                                                                                                                                                     
  Wards                                           2/897               0.2       5/882       0.6    9/871       1.0    10/882      1.1    10/867      1.2    9/944       1.0    12/1,046    1.1    19/939      2.0    \< 0.001   ↑
  Ciprofloxacin non-susceptible                                                                                                                                                                                                 
  Wards                                           265/1,037           25.6      282/1,034   27.3   311/1,045   29.8   358/1,097   32.6   369/1,095   33.7   325/1,115   29.1   433/1,331   32.5   386/1,198   32.2   \< 0.001   ↑
  Trimethoprim/sulfamethoxazole non-susceptible                                                                                                                                                                                 
  Wards                                           376/1,026           36.6      365/918     39.8   362/930     38.9   413/1,034   39.9   385/1,051   36.6   335/1,059   31.6   430/1,251   34.4   383/1,154   33.2   \< 0.001   ↓
  *Enterobacter*spp.                                                                                                                                                                                                            
  Ceftazidime non-susceptible                                                                                                                                                                                                   
  Wards                                           98/222              44.1      66/202      32.7   69/193      35.8   61/202      30.2   67/181      37.0   65/197      33.0   42/185      22.7   61/191      31.9   0.001      ↓
  Imipenem non-susceptible                                                                                                                                                                                                      
  Wards                                           34/219              15.5      22/200      11.0   35/194      18.0   31/200      15.5   32/177      18.1   36/195      18.5   32/185      17.3   39/191      20.4   0.044      ↑
  Meropenem non-susceptible                                                                                                                                                                                                     
  Wards                                           17/196              8.7       15/181      8.3    14/165      8.5    21/176      11.9   13/126      10.3   24/156      15.4   16/154      10.4   22/166      13.3   0.042      ↑
  Ciprofloxacin non-susceptible                                                                                                                                                                                                 
  Wards                                           44/222              19.8      22/201      10.9   25/194      12.9   24/201      11.9   22/179      12.3   29/196      14.8   16/187      8.6    21/189      11.1   0.023      ↓
  Tobramycin non-susceptible                                                                                                                                                                                                    
  Wards                                           70/214              32.7      33/199      16.6   38/184      20.7   31/188      16.5   36/170      21.2   38/165      23.0   26/165      15.8   22/150      14.7   0.001      ↓
  Multiresistance                                                                                                                                                                                                               
  Wards                                           34/205              16.6      16/197      8.1    18/182      9.9    16/181      8.8    16/167      9.6    20/162      12.3   10/161      6.2    12/145      8.3    0.034      ↓
  *Klebsiella pneumoniae*                                                                                                                                                                                                       
  Ceftazidime non-susceptible                                                                                                                                                                                                   
  Wards                                           470/761             61.8      434/698     62.2   366/635     57.6   396/689     57.5   391/682     57.3   416/726     57.3   421/743     56.7   445/761     58.5   0.027      ↓
  ICU                                             567/612             92.6      589/652     90.3   504/556     90.6   397/455     87.3   387/442     87.6   349/403     86.6   396/453     87.4   364/411     88.6   0.001      ↓
  Imipenem non-susceptible                                                                                                                                                                                                      
  Wards                                           380/761             49.9      347/696     49.9   294/630     46.7   320/685     46.7   320/681     47.0   346/726     47.7   375/743     50.5   399/761     52.4   0.021      ↑^a^
  ICU                                             536/608             88.2      567/653     86.8   461/552     83.5   366/454     80.6   369/439     84.1   341/404     84.4   399/453     88.1   351/409     85.8   \<0.001    ↓^b^
  Meropenem non-susceptible                                                                                                                                                                                                     
  Wards                                           305/678             45.0      321/638     50.3   281/606     46.4   298/598     49.8   302/602     50.2   322/636     50.6   342/630     54.3   379/689     55.0   \< 0.001   ↑
  ICU                                             472/584             80.8      507/618     82.0   432/538     80.3   349/432     80.8   333/403     82.6   327/377     86.7   385/432     89.1   358/412     86.9   \< 0.001   ↑
  Ciprofloxacin non-susceptible                                                                                                                                                                                                 
  ICU                                             555/612             90.7      584/653     89.4   497/556     89.4   384/455     84.4   381/442     86.2   342/403     84.9   392/454     86.3   361/412     87.6   0.005      ↓
  Gentamicin non-susceptible                                                                                                                                                                                                    
  Wards                                           133/763             17.4      108/697     15.5   108/635     17.0   140/685     20.4   148/683     21.7   142/726     19.6   202/743     27.2   225/763     29.5   \< 0.001   ↑
  ICU                                             166/611             27.2      188/651     28.9   234/557     42.0   201/456     44.1   171/437     39.1   180/405     44.4   223/455     49.0   206/413     49.9   \< 0.001   ↑
  Tobramycin non-susceptible                                                                                                                                                                                                    
  Wards                                           458/744             61.6      427/682     62.6   304/537     56.6   335/587     57.1   354/640     55.3   293/564     52.0   319/610     52.3   313/589     53.1   \< 0.001   ↓
  ICU                                             509/570             89.3      556/634     87.7   420/472     89.0   309/370     83.5   327/408     80.1   248/288     86.1   268/327     82.0   211/256     82.4   \< 0.001   ↓
  Cefoxitin non-susceptible                                                                                                                                                                                                     
  ICU                                             481/529             90.9      488/551     88.6   367/483     76.0   276/364     75.8   271/364     74.5   266/360     73.9   309/425     72.7   313/395     79.2   \< 0.001   ↓
  Multiresistance                                                                                                                                                                                                               
  Wards                                           391/738             53.0      372/680     54.7   272/536     50.7   282/587     48.0   308/639     48.2   252/564     44.7   268/610     43.9   271/588     46.1   \< 0.001   ↓
  ICU                                             498/569             87.5      540/628     86.0   405/471     86.0   296/369     80.2   318/406     78.3   234/288     81.3   254/325     78.2   208/256     81.3   \< 0.001   ↓
  *Pseudomonas aeruginosa*                                                                                                                                                                                                      
  Piperacillin/tazobactam non-susceptible                                                                                                                                                                                       
  ICU                                             179/435             41.1      88/283      31.1   62/197      31.5   73/339      21.5   98/304      32.2   54/209      25.8   65/256      25.4   47/221      21.3   \< 0.001   ↓
  Ceftazidime non-susceptible                                                                                                                                                                                                   
  ICU                                             226/433             52.2      173/353     49.0   182/346     52.6   201/389     51.7   153/313     48.9   102/237     43.0   118/274     43.1   97/237      40.9   \< 0.001   ↓
  Imipenem non-susceptible                                                                                                                                                                                                      
  Wards                                           222/404             55.0      240/425     56.5   258/410     62.9   319/455     70.1   258/377     68.4   282/409     68.9   297/446     66.6   283/448     63.2   \< 0.001   ↑^b^
  ICU                                             315/431             73.1      252/354     71.2   255/346     73.7   290/389     74.6   250/313     79.9   192/237     81.0   214/273     78.4   179/235     76.2   0.005      ↑
  Meropenem non-susceptible                                                                                                                                                                                                     
  Wards                                           157/406             38.7      162/414     39.1   167/398     42.0   208/432     48.1   117/348     33.6   162/393     41.2   160/425     37.6   168/423     39.7   0.004      ↑^b^
  ICU                                             264/435             60.7      206/325     63.4   203/335     60.6   244/385     63.4   177/301     58.8   118/228     51.8   122/254     48.0   116/230     50.4   \< 0.001   ↓
  Ciprofloxacin non-susceptible                                                                                                                                                                                                 
  ICU                                             244/435             56.1      174/352     49.4   185/346     53.5   205/391     52.4   148/315     47.0   106/240     44.2   98/275      35.6   96/238      40.3   \< 0.001   ↓
  Tobramycin non-susceptible                                                                                                                                                                                                    
  Wards                                           123/391             31.5      121/411     29.4   121/354     34.2   141/399     35.3   98/357      27.5   76/286      26.6   101/357     28.3   91/338      26.9   0.039      ↓
  ICU                                             214/395             54.2      165/340     48.5   144/289     49.8   169/331     51.1   125/276     45.3   60/159      37.7   68/205      33.2   60/163      36.8   \< 0.001   ↓
  Gentamicin non-susceptible                                                                                                                                                                                                    
  Wards                                           138/414             33.3      141/426     33.1   154/414     37.2   163/457     35.7   101/374     27.0   106/409     25.9   137/451     30.4   123/449     27.4   \< 0.001   ↓
  ICU                                             239/433             55.2      185/353     52.4   170/345     49.3   170/390     43.6   126/305     41.3   87/240      36.3   94/276      34.1   79/237      33.3   \< 0.001   ↓
  Amikacin non-susceptible                                                                                                                                                                                                      
  ICU                                             201/434             46.3      147/353     41.6   147/347     42.4   183/383     47.8   130/309     42.1   90/237      38.0   91/274      33.2   81/235      34.5   \< 0.001   ↓
  Multiresistance                                                                                                                                                                                                               
  *ICU*                                           156/429             36.4      116/342     33.9   127/337     37.7   155/376     41.2   118/305     38.7   72/235      30.6   74/271      27.3   73/235      31.1   0.018      ↓
  *Acinetobacter baumannii*                                                                                                                                                                                                     
  Cefepime non-susceptible                                                                                                                                                                                                      
  Wards                                           265/299             88.6      285/335     85.1   324/369     87.8   282/316     89.2   323/347     93.1   398/442     90.0   369/401     92.0   444/459     96.7   \< 0.001   ↑
  ICU                                             607/629             96.5      562/619     90.8   526/570     92.3   460/474     97.0   491/495     99.2   485/495     98.0   481/491     98.0   425/434     97.9   \< 0.001   ↑
  Imipenem non-susceptible                                                                                                                                                                                                      
  Wards                                           243/303             80.2      290/337     86.1   322/363     88.7   281/319     88.1   300/331     90.6   369/415     88.9   351/389     90.2   416/445     93.5   \< 0.001   ↑
  ICU                                             555/576             96.4      610/637     95.8   552/567     97.4   449/460     97.6   483/486     99.4   472/482     97.9   470/475     98.9   419/426     98.4   \< 0.001   ↑
  Meropenem non-susceptible                                                                                                                                                                                                     
  Wards                                           244/306             79.7      282/324     87.0   321/362     88.7   259/300     86.3   290/319     90.9   358/404     88.6   346/380     91.1   423/448     94.4   \< 0.001   ↑
  ICU                                             605/635             95.3      552/576     95.8   528/546     96.7   420/437     96.1   422/428     98.6   405/418     96.9   441/447     98.7   419/427     98.1   \< 0.001   ↑
  Tobramycin non-susceptible                                                                                                                                                                                                    
  Wards                                           132/284             46.5      149/330     45.2   204/325     62.8   179/270     66.3   204/322     63.4   232/316     73.4   189/276     68.5   231/271     85.2   \< 0.001   ↑
  ICU                                             339/562             60.3      412/632     65.2   341/491     69.5   311/411     75.7   352/443     79.5   317/371     85.4   290/346     83.8   227/252     90.1   \< 0.001   ↑
  Amikacin non-susceptible                                                                                                                                                                                                      
  Wards                                           208/291             71.5      218/301     72.4   248/344     72.1   231/304     76.0   244/316     77.2   295/390     75.6   276/343     80.5   338/408     82.8   \< 0.001   ↑
  ICU                                             484/594             81.5      451/598     75.4   405/536     75.6   379/431     87.9   396/445     89.0   388/430     90.2   370/394     93.9   299/332     90.1   \< 0.001   ↑
  Gentamicin non-susceptible                                                                                                                                                                                                    
  Wards                                           199/306             65.0      261/337     77.4   303/371     81.7   267/328     81.4   270/335     80.6   340/421     80.8   330/393     84.0   395/448     88.2   \< 0.001   ↑
  ICU                                             474/610             77.7      548/658     83.3   512/585     87.5   427/466     91.6   457/491     93.1   462/488     94.7   447/480     93.1   399/426     93.7   \< 0.001   ↑
  Ciprofloxacin non-susceptible                                                                                                                                                                                                 
  Wards                                           264/298             88.6      308/336     91.7   338/370     91.4   298/326     91.4   315/338     93.2   381/421     90.5   360/394     91.4   426/445     95.7   0.009      ↑
  Multiresistance                                                                                                                                                                                                               
  Wards                                           206/291             70.8      215/285     75.4   245/329     74.5   226/297     76.1   240/314     76.4   292/388     75.3   273/339     80.5   338/404     83.7   \< 0.001   ↑
  ICU                                             482/590             81.7      447/551     81.1   403/502     80.3   372/422     88.2   390/438     89.0   385/429     89.7   366/393     93.1   297/331     89.7   \< 0.001   ↑
  *Staphylococcus aureus*                                                                                                                                                                                                       
  Oxacillin non-susceptible^c^                                                                                                                                                                                                  
  ICU                                             43/90               47.8      57/104      54.8   58/99       58.6   41/74       55.4   34/74       45.9   27/57       47.4   30/65       46.2   25/75       33.3   0.01       ↓
  Ciprofloxacin non-susceptible                                                                                                                                                                                                 
  Wards                                           67/268              25.0      77/328      23.5   122/463     26.3   162/513     31.6   118/469     25.2   145/523     27.7   193/595     32.4   189/556     34.0   0.001      ↑
  ICU                                             26/49               53.1      40/74       54.1   48/85       56.5   27/65       41.5   23/67       34.3   21/54       38.9   22/59       37.3   20/70       28.6   \< 0.001   ↓
  Gentamicin non-susceptible                                                                                                                                                                                                    
  Wards                                           52/573              9.1       33/570      5.8    36/623      5.8    38/601      6.3    26/512      5.1    26/575      4.5    33/653      5.1    31/630      4.9    0.003      ↓
  ICU                                             26/98               26.5      28/104      26.9   29/99       29.3   19/72       26.4   6/76        7.9    8/57        14.0   4/65        6.2    5/75        6.7    \< 0.001   ↓
  Multiresistance                                                                                                                                                                                                               
  Wards                                           40/552              7.2       24/569      4.2    27/622      4.3    32/598      5.4    18/502      3.6    21/571      3.7    18/644      2.8    20/630      3.2    \< 0.001   ↓
  ICU                                             18/88               20.5      19/104      18.3   25/99       25.3   17/72       23.6   6/74        8.1    6/57        10.5   4/65        6.2    3/75        4.0    \< 0.001   ↓
  *Enterococcus faecalis*                                                                                                                                                                                                       
  Gentamicin HLR                                                                                                                                                                                                                
  Wards                                           128/341             37.5      118/342     34.5   100/403     24.8   70/360      19.4   65/326      19.9   48/348      13.8   65/379      17.2   47/417      11.3   \< 0.001   ↓
  ICU                                             85/173              49.1      60/190      31.6   52/195      26.7   33/147      22.4   25/125      20.0   16/138      11.6   29/183      15.8   17/143      11.9   \< 0.001   ↓^b^
  Streptomycin HLR                                                                                                                                                                                                              
  Wards                                           145/325             44.6      118/325     36.3   84/390      21.5   54/323      16.7   51/287      17.8   39/318      12.3   46/342      13.5   35/383      9.1    \< 0.001   ↓
  ICU                                             89/171              52.0      65/182      35.7   63/194      32.5   24/136      17.6   14/110      12.7   12/128      9.4    13/157      8.3    10/130      7.7    \< 0.001   ↓^d^
  *Enterococcus faecium*                                                                                                                                                                                                        
  Gentamicin HLR                                                                                                                                                                                                                
  Wards                                           121/240             50.4      94/214      43.9   77/235      32.8   63/236      26.7   41/204      20.1   33/215      15.3   57/255      22.4   43/279      18.9   \< 0.001   ↓^b^
  ICU                                             67/123              54.5      41/107      38.3   27/111      24.3   25/95       26.3   16/77       20.8   8/84        9.5    21/102      20.6   22/92       16.9   \< 0.001   ↓^b^
  Streptomycin HLR                                                                                                                                                                                                              
  Wards                                           145/226             64.2      113/205     55.1   69/224      30.8   63/220      28.6   43/183      23.5   50/201      24.9   66/238      27.7   54/268      20.1   \< 0.001   ↓^b^
  ICU                                             73/122              59.8      43/103      41.7   36/111      32.4   24/88       27.3   14/69       20.3   12/80       15.0   17/91       18.7   24/81       29.6   \< 0.001   ↓^b^

AMR: antimicrobial resistance; HLR: high-level resistance; ICU: intensive care unit; NS: non-susceptible; NS/tested: number of non-susceptible isolates for an antibiotic divided by the number of isolates tested for the respective antibiotic; WHONET-Greece: Greek electronic surveillance system for monitoring antimicrobial resistance in hospitals based on routine data.

'**↑**' and '**↓**' indicate significant increasing and decreasing trends, respectively.

^a^A significant trend was only observed in the last 4 years of the study (2014--2017).

^b^ A significant trend was only observed in the first 4 years of the study (2010--2013).

^c^ Oxacillin non-susceptibility is used to test for meticillin resistance in *S. aureus* (MRSA).

^d^ A significant non-linear trend.

### *Escherichia coli*

During the study period, for third-generation cephalosporins, the annual proportions of *E. coli* isolates non susceptible for ceftazidime from patients hospitalised in wards, significantly increased from 11.3% in 2010 to 14.7% in 2017 (p = 0.012). An apparent increase was also observed for rates of cefotaxime non-susceptible isolates, from 18.9% (190/1,005) in 2010 to 21.2% (215/1,013) in 2017. Meropenem non-susceptible isolates represented 0.2% of isolates in 2010 and their proportion increased significantly over time, reaching 2.0% in 2017 (p \< 0.001). Moreover, an increasing trend in rates of isolates non-susceptible to ciprofloxacin was also observed (p \< 0.001) starting at 25.6% in 2010 to reach 32.2% in 2017. On the contrary, the proportions of trimethoprim/sulfamethoxazole non-susceptible isolates decreased during the study period (p \< 0.001). Regarding non-susceptibility to aminoglycosides, no trend was found for both gentamicin and tobramycin from 2010 to 2017.

### *Proteus mirabilis*

Third-generation cephalosporins non-susceptibility among *P. mirabilis* isolates from patients hospitalised in the wards was 25.0% (39/156) in 2010, with an apparent increase to 34.4% (67/195) in 2013 and a decrease to 17.6% (36/204) in 2017, while in ICUs the rate of non-susceptible isolates was 52.3% (56/107) in 2010 reaching 65.3% (47/72) in 2017. No trend was observed in ciprofloxacin non-susceptibility, remaining stable at approximately 45% and above 58% in *P. mirabilis* isolates from patients hospitalised in wards and ICUs respectively. Regarding non-susceptibility to aminoglycosides, the proportions of gentamicin non-susceptible isolates increased from 18.6% (29/156) to 25.1% (51/203) (p = 0.03) and from 30.2% (32/106) to 54.9% (39/71) (p = 0.001) from 2010 to 2017 for patients hospitalised in wards and ICUs, respectively.

### *Enterobacter* spp.

Rates of carbapenem non-susceptibility in *Enterobacter*spp. isolates from hospital wards showed increasing trends from 15.5% to 20.4% for imipenem and from 8.7% to 13.3% for meropenem in 2010 and 2017 respectively (both p = 0.04). On the contrary, decreasing trends were found for the proportions of isolates non susceptible to ceftazidime (from 44.1% to 31.9%, p = 0.001), tobramycin (from 32.7% to 14.7%, p = 0.001), ciprofloxacin (from 19.8% to 11.1%, p = 0.023) and with multiresistance (from 16.6% to 8.3%, p = 0.034) ([Figure 3](#f3){ref-type="fig"}).

![Significant non-susceptibility trends concerning the main pathogen-antimicrobial combinations for (a) *Escherichia coli*, (b) *Enterobacter* spp., (c) *Staphylococcus aureus,* (d) *Enterococcus faecalis* and *faecium* in wards and (e) *Staphylococcus aureus* in ICUs, for patients hospitalised in the 25 hospitals participating in the WHONET-Greece AMR network, 2010--2017](1900516-f3){#f3}

### *Klebsiella pneumoniae*

Rates of meropenem non-susceptibility increased with proportions of isolates ranging from 45.0% to 55.0% and from 80.8% to 86.9% in patients hospitalised in wards and ICUs respectively from 2010 to 2017 (both p \< 0.001). Regarding the percentages of imipenem non-susceptible isolates, we found a significant decreasing trend in ICUs during the first 4 years (from 88.2% to 80.6%, p \< 0.001) and an increasing trend during the last four ones in wards (from 47.0% to 52.4%, p = 0.021). High proportions of isolates with ceftazidime non-susceptibility were observed; however, a decreasing trend in both wards (from 61.8% to 58.5%) and ICUs (from 92.6% to 88.6%) (p = 0.027 and p = 0.001, respectively) was found from 2010 to 2017. Non-susceptibility rates to fluoroquinolones did not change significantly over time for *K. pneumoniae* isolates from patients hospitalised in wards while a significant decrease was observed in isolates from ICU patients (p \< 0.005). Regarding aminoglycosides, an increasing trend in rates of gentamicin non-susceptibility was found among isolates from both wards and ICUs (from 17.4% to 29.5% and from 27.2% to 49.9% respectively, both p \< 0.001). On the contrary, a decreasing trend in rates of tobramycin non-susceptibility was observed among isolates from both wards and ICUs (both p \< 0.001). Finally, multiresistance rates, meaning simultaneous non-susceptibility to ceftazidime, tobramycin and ciprofloxacin, decreased significantly over the studied years, from 53.0% to 46.1% among isolates from wards and from 87.5% to 81.3% among those from ICUs (both p \< 0.001) ([Figure 4](#f4){ref-type="fig"}).

![Significant non-susceptibility trends of the three main carbapenem-resistant Gram-negative pathogens from patients hospitalised in the wards and ICUs of the 25 hospitals participating in the WHONET-Greece AMR network, 2010--2017](1900516-f4){#f4}

### *Pseudomonas aeruginosa*

Decreasing trends were found in the proportions of non-susceptible *P. aeruginosa*isolates to almost all clinical relevant antibiotics with the exception of imipenem. In terms of carbapenems, the percentage of imipenem non-susceptible isolates significantly increased among isolates from patients hospitalised in wards (p \< 0.001) and ICUs (p = 0.005), while proportions of non-susceptible meropenem isolates remained stable during the study period or even showed a decreasing trend in ICUs (from 60.7% to 50.4%, p \< 0.001). The proportions of isolates with ceftazidime non-susceptibility also presented a decreasing trend in ICUs from 52.2% to 40.9% (p \< 0.001).

Finally, the rates of isolates non-susceptible to fluoroquinolones and aminoglycosides were found to significantly decrease during the study period (both p \< 0.001) ([Figure 4](#f4){ref-type="fig"}).

### *Acinetobacter baumannii*

From 2010 to 2017, the proportion of non-susceptible isolates to cefepime, imipenem, meropenem, aminoglycosides, as well as those with multiresistance increased significantly (all p \< 0.001) in both wards and ICUs of the participating hospitals. Of note, the proportion of carbapenem resistant isolates was consistently very high in both wards and ICUs during the whole study period, ranging for meropenem from 79.7% and 95.3% in 2010 to 94.4% and 98.1% in 2017 in wards and ICUs respectively ([Figure 4](#f4){ref-type="fig"}).

### *Staphylococcus aureus*

A significant decreasing trend was observed in the proportion of meticillin-resistant *S. aureus* (MRSA) from ICU patients, ranging from 47.8% in 2010 to 33.3% in 2017 (p = 0.01) as well as for ciprofloxacin, ranging from 53.1% in 2010 to 28.6% in 2017 (p \< 0.001) ([Figure 3e](#f3){ref-type="fig"}). In contrast, an increasing trend was found for the rates of non-susceptibility to ciprofloxacin in *S. aureus* isolates from patients hospitalised in wards, ranging from 25.0% in 2010 to 34.0% in 2017 (p = 0.001). Finally, the proportions of isolates with non-susceptibility to gentamicin as well as with a combined non-susceptibility to meticillin and gentamicin were significantly decreased in both wards and ICUs (all p \< 0.004), ([Figure 3c,e](#f3){ref-type="fig"}).

### *Enterococcus faecalis* and *Enterococcus faecium*

Regarding rates of isolates with HLR to gentamicin and streptomycin, decreasing trends were observed among both *E. faecalis* and *E. faecium* isolates ([Figure 3d](#f3){ref-type="fig"}). The proportions of isolates non-susceptible to vancomycin among *E. faecalis* bloodstream isolates from patients in ICUs decreased from 7.3% (13/179) to 1.4% (2/148) from 2010 to 2017. The rates of isolates non-susceptible to vancomycin from 2010 to 2017 among *E. faecium* isolates was found at similar levels in wards (21.6% (53/245) to 28.4% (76/268)) and ICUs (22.7% (29/128) to 28.4% (31/109)), however, no linear increasing trend was found in either hospital departments.

Discussion
==========

We analysed the RIF and the routine susceptibility data for 50,488 key bloodstream isolates recovered from patients hospitalised in wards and ICUs of 25 hospitals participating in the WHONET-Greece AMR surveillance network during an 8-year period and report several major findings regarding the observed trends over time.

*E. coli* was the most common cause of bloodstream infection (BSI) in patients hospitalised in wards. The high proportion of isolates with non-susceptibility to third-generation cephalosporins with an increasing trend over the years, coupled with similar trends for proportions of isolates with non-susceptibility to fluoroquinolones is a serious concern since prompt administration of an effective empirical antimicrobial treatment is essential at both patient and public health level. Moreover, over the years, an increasing trend was observed for the proportion of ward-patient *E. coli*isolates, which were non-susceptible to carbapenems. According to the results of the European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) published in 2017 \[[@r5]\] carbapenemase-producing *E. coli* are becoming more widespread in Europe, thus requiring close surveillance. Acquisition of carbapenemase genes by *E. coli* \[[@r5]-[@r12]\] is concerning, since *E. coli* spreads in the community more readily than *K. pneumoniae*. Moreover *E. coli* from the digestive tract of asymptomatic carriers are common vectors of promiscuous plasmids, which could also accelerate spread of resistance \[[@r5]\].

The observed significant increasing trend of non-susceptible ciprofloxacin isolates is possibly consistent with further dissemination of sequence type (ST)131 strains which Mavroidi et al. found \[[@r13]\] responsible for the increasing fluoroquinolone resistance during 2011 in Central Greece. *E. coli* ST131 is associated with human urinary tract infections and BSIs and was first described in 2008 as a major clone linked to the spread of extended-spectrum beta-lactamase CTX-M-15. It has since disseminated worldwide and strains resistant to fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole and carbapenems have been reported, limiting treatment options for this pathogen \[[@r13],[@r14]\].

Regarding *K. pneumoniae*, the major finding was the increasing trend in the proportion of isolates with meropenem non-susceptibility, not only in the ICUs but also in wards of the participating hospitals. This finding may reflect the evolving molecular epidemiology of carbapenemase-producing *K. pneumoniae*. It is well documented that Greece has been facing high rates of carbapenem resistance among clinical *K. pneumoniae* since 2002. This was initially due to a multiclonal plasmid-mediated epidemic of Verona Integron-encoded Metallo-beta-lactamase (VIM)-producers during the period 2002--2007 \[[@r15]\]. From 2007, the introduction and rapid clonal dissemination of mainly ST258 *K. pneumoniae* carbapenemase (KPC)-producers occurred \[[@r16],[@r17]\]. KPC has since been the predominant carbapenemase among the hospital *K. pneumoniae* population. However, starting 2011, *K. pneumoniae* ST11 producing New Delhi Metallo-beta-lactamase (NDM)-1 emerged in the country and was identified retrospectively as the cause of a prolonged outbreak of healthcare-associated infections in a University hospital at North-Western Greece \[[@r18]\]. Two years later, NDM-1 producers belonging to ST11 were reported in Athens \[[@r19]\]. Of note, soon after the introduction of NDM in the country, the EuSCAPE project conducted between November 2013 and April 2014 in 10 hospitals all over Greece found it to rank as the second most frequent carbapenemase \[[@r5]\]. This was also reported by a subsequent nationwide multicentre study during the period 2014--2016 \[[@r20]\], indicating further dissemination. Moreover, according to a report published in 2015 \[[@r21]\], while KPC-2 production provides Enterobacteriaceae with intermediate resistance or even decreased susceptibility to meropenem in many cases, NDM-1 production allows HLR to meropenem. Regarding Oxacillinase (OXA)-48-carbapenemase, in 2012 an outbreak of OXA-48 carbapenemase-producing *K. pneumoniae* ST11 was recorded for the first time in the country \[[@r22]\]. Nevertheless, no major epidemics of OXA-48 producing *K. pneumoniae* were recorded since their introduction in Greece and OXA-48 remained rare during the period 2014--2016 \[[@r20]\]. The ongoing carbapenem and/or colistin-resistant Enterobacteriaceae (CCRE) project as part of the European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) will provide updated and more detailed information on the distribution of carbapenemase-producing *K. pneumoniae* in Greece as well as in Europe.

The observed increasing trend in the proportion of *K. pneumoniae* isolates non susceptible to gentamicin over the study period in both wards and ICUs, reaching respectively up to 30% and 50%, is of concern, since gentamicin was found to be the most active in vitro aminoglycoside in clinical use, among the four available (amikacin, gentamicin, tobramycin and netilmicin) in a nationwide multicentre study between 2014 and 2016 of 300 carbapenem-resistant *K. pneumoniae* isolates from Greek hospitals \[[@r23]\].

For *P. aeruginosa,* the decreasing trends in rates of isolates with non-susceptibility for all of the studied antibiotics except imipenem, for which an increasing non-susceptibility trend was found, could reflect the decrease in isolation of VIM-producing *P. aeruginosa*, in the last 20 years \[[@r24],[@r25]\] and the increasing role of non-enzymatic mechanisms of carbapenem resistance among this bacterial population. Specifically, the inactivation, downregulation, or even loss of OprD porin is well documented to confer resistance only to imipenem \[[@r26],[@r27]\]. The possible relative decreasing proportion of VIM producers among the *P. aeruginosa* carbapenem-resistant population could affect also other antibiotic classes like aminoglycosides and fluoroquinolones since VIM producers commonly exhibit multidrug resistant phenotypes and thus could explain the overall decreasing trend we found for aminoglycosides and quinolones.

With respect to *A. baumannii*, the observed significant increasing trend in its RIF in the wards and its predominance in the ICUs of the participating hospitals, coupled with increasing trends in the proportion of isolates non-susceptible to almost all antimicrobials and especially to carbapenems is of outstanding importance. However, more concerning are reports of colistin-resistant/carbapenem-resistant *A. baumannii* isolates which constitute a great challenge for both clinical practice and public health \[[@r28]\]. Molecular epidemiology studies at the national level have revealed that since 2010, OXA-23 producing *A. baumannii* appeared and further disseminated in Greece replacing the former endemic OXA-58 producers and displaying higher minimum inhibitory concentrations (MIC)s to carbapenems due to their higher hydrolytic activity \[[@r29]\]. The latter characteristic has been considered as a comparative advantage to survive and predominate in the hospital setting \[[@r30]\]. A nationwide study from 2015 confirmed that carbapenem-resistant *A. baumannii* isolates in Greek hospitals produce almost exclusively the OXA-23 carbapenemase and they belong mainly to the international clone (IC) 2 and to a lesser extent, IC1 \[[@r29]\].

For *S. aureus*, the decline during the study period in the percentage of MRSA is in alignment with the situation in a majority of European Union (EU)/European Economic Area (EEA) countries where MRSA percentages seem to be stabilising or even decreasing \[[@r31]\]. The decline has been reported for an even larger time period (2000--2015) from a study of MRSA BSI cases in a big University hospital in Greece, where the authors reported a decreasing trend in the incidence of MRSA BSIs from 1.69 per 10,000 patient days in 2000 to 1.39 per 10,000 patient days in 2015 (p = 0.038) and in prevalence from 64.7% to 36.4% (p = 0.008), respectively. The observed decline in MRSA BSI rates was associated with changes in the population structure of the organism; the pandemic healthcare-acquired (HA)-MRSA clone ST239-III progressively declined, parallel to the increased isolation frequency of two clonal complexes (CCs): HA-MRSA CC5 and CA-MRSA CC80 \[[@r32]\].

Regarding enterococci, Greece is among the European countries with the lowest percentages in both *E. faecalis* and *E. faecium* of gentamicin HLR, at least since 2015 (<https://atlas.ecdc.europa.eu>). Furthermore, the observed significant decreasing trend during our study period is in accordance with that of the EU/EEA between 2014 and 2017 as well as the trend from almost one fourth of the countries that report national AMR data in EARS-net \[[@r31]\]. On the other hand, the observed level of *E. faecium* non-susceptibility to vancomycin, even without a significant trend over time, is a cause of concern and highlights the need for close monitoring. Contrary to many other bacterium--antimicrobial group combinations under surveillance by EARS-Net, no distinct geographical pattern could be seen for vancomycin-resistant *E. faecium*, as high resistance levels were reported from countries in southern, eastern and northern Europe \[[@r31]\].

As it is clearly indicated by the aforementioned data, AMR is a dynamic phenomenon with new resistance mechanisms or combination of resistance mechanisms that can emerge or be introduced and be disseminated rapidly in different bacterial species. In this respect, the Greek continuous electronic AMR surveillance system, focusing on the overall epidemiology of susceptible and resistant bacteria and assisted by an early warning system for new or important resistance phenotypes has developed into a successful, cost-effective tool for the surveillance of AMR in the country.

In more details, during the 2000s, in order to trace the emergence and spread of new resistance mechanisms and to further characterise them, each hospital laboratory had to report immediately through the early warning system certain new or important resistant phenotypes to both the Hospital Infection Control Committee and the Greek Centre for Diseases Control and Prevention and also to send the isolates for further testing in the relevant reference laboratories. It was this surveillance process that enabled Greek Public Health authorities to timely identify the emergence of carbapenem resistant Gram-negative pathogens and especially VIM-producing *P. aeruginosa* \[[@r25]\], VIM- \[[@r33]\] and KPC-producing *K. pneumoniae* \[[@r16],[@r17]\] in the hospital setting. During the 2010s, through the National Action Plan for the prevention and control of nosocomial infections caused by carbapenem resistant Gram-negative pathogens in healthcare settings (the PROKROUSTIS project) and subsequently the relevant national legislation for the surveillance of healthcare-associated infections, protocols for sending important isolates to the national surveillance centres for confirmation and characterisation have been implemented. This process enabled us to timely identify the new entry of NDM and OXA-48 carbapenemases in the country \[[@r18],[@r19],[@r22]\] as well as OXA-23 in *A. baumannii* \[[@r28]-[@r30]\]. Overall, since 1995, WHONET-Greece has been providing valuable background information on the evolution of the complex epidemiology of AMR to be used in developing the strategy to combat this problem at the hospital, regional and national level.

This study has some limitations. The first may result from the potential impact of biases in sampling practices of routine clinical diagnostic data, since, in general, routine clinical data would often overestimate resistance because of the tendency to culture specimens from patients with treatment failures and/or complicated medical histories. This problem could be further enhanced by selective culturing and antimicrobial susceptibility testing due to the ongoing financial crisis in Greece. However, the biases are consistent from year to year. Moreover, the level of financial crisis, in terms of hospital budget cuts, is not as extensive as to affect critical diagnostic procedures, such as blood culturing (data not shown). Therefore one may still identify important temporal trends using routine AMR data from bacteraemias. Another possible limitation is that, while colistin has been increasingly used since 2010 in Greece as a fundamental companion drug for the treatment of the carbapenem-resistant Enterobacteriaceae *P. aeruginosa* and *A. baumannii*, we could neither study colistin non-susceptibility prevalence nor its evolution over time in the period 2010--2017. This was mainly due to technical challenges of testing colistin susceptibility with the gradient tests or semiautomatic instruments used in the hospitals' laboratories during the study. However, based on the recently issued recommendations from CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@r34]\], the Greek National Antibiogram Committee (NAC) now advises hospitals to use broth microdilution as the gold-standard method for colistin MIC determination, and the increasing compliance of hospital laboratories will likely enable the WHONET-Greece system to study colistin non-susceptibility trends prospectively in the forthcoming years. A third limitation is that we could not take some important data under consideration in our analysis, such as dates of hospital admission and/or discharge, details on the treatment received by patients as well as clinical outcomes. Indeed, at present, Greek hospital clinical laboratories do not have direct access to patients' data even if basic patient demographic data are available. This limitation could be solved by linking routine microbiology data with other existing relevant datasets in the hospital, as part of the overall national strategy to upgrade health information systems.

To achieve this, as well as a comprehensive AMR surveillance system in the country, the WHONET software could be used as the basic tool for all microbiology laboratories to input their data. As all laboratories enter or transfer their reports into WHONET, the resulting files will be inter-compatible and will enable compiling to inform both national and international multicentre surveillance networks \[[@r35]\] without any additional microbiology staff's dedicated time.

Monitoring AMR trends is an indiscernible means of assessing and possibly modifying the implemented national initiatives and interventions according to the recent national legislation. Moreover, timely and targeted dissemination of national surveillance data to all major stakeholders at European level should become an essential component of efforts to control the threat of AMR in European Union and European Economic Area countries and reduce its burden. In this context, we have found the use of routine hospital laboratory data from the Greek continuous electronic AMR surveillance system, to be important not only at hospital and national level but European level as well.
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